China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds
June 21 (Reuters) - Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a similar drug sold by Novo Nordisk (NOVOb.CO), opens new tab, according to a late-stage study published on Saturday.
The drug, called ecnoglutide, belongs to a class of drugs that include Novo's Wegovy called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness.
"It's going to be competitive," said Dr. Tricia Tan of Imperial College London, who wrote a piece accompanying the data which appeared in medical journal The Lancet.
Tan said additional GLP-1s on the market could potentially drive prices down and improve access globally.
"It's great to have competition in the market. It's been extremely frustrating - I work in the National Health Service and patients are not getting access to these drugs."
Patients have seen even better results with Eli Lilly's (LLY.N), opens new tab Zepbound, which stimulates GLP-1 as well as a second gut hormone called GIP. More than 20% weight loss was reported in clinical trials.
According to the Sciwind Phase 3 study, 499 patients were given 1.2 mg, 1.8 mg or 2.4 mg of ecnoglutide as a subcutaneous injection once weekly for 48 weeks, with 165 patients assigned to receive a placebo. The study was conducted at 36 medical centers across China.
The patients who received the 1.2 mg dose lost an average of 9.9% of their body weight after 48 weeks, and those who received the 1.8 mg dose lost an average of 13.3% of their body weight. Patients on the 2.4 mg dose lost an average of 15.4% of their body weight.
The patients on placebo lost an average of 0.3% of their body weight over the period.
The side-effect profile is not significantly different from the other weight loss drugs. Many of the patients given ecnoglutide experienced decreased appetite and gastrointestinal problems, including diarrhea, nausea and vomiting, the study authors wrote.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
5 hours ago
- The Sun
Watch moment iconic car maker enters space race after successfully launching reusable rocket
Eliana Nunes Published: Invalid Date, THIS is the spectacular moment one of the world's largest car manufacturers successfully launched a reusable rocket. Honda R&D - the research and development arm of Honda Motor - landed a rocket for the first time on Tuesday - after it reached an altitude of nearly 1,000 feet. 4 The experimental reusable rocket reached an altitude of 890 feet during its test flight - staying aloft for 56.6 seconds. It landed just 14.6 inches from its target touchdown point at the carmaker's test facility in northern Japan, according to Honda. Weighing in at 2,890 pounds when fully fuelled (1,984 pounds dry), the rocket is 20.7 feet tall and measured 2.8 feet in diameter. Honda's rocket has become the first prototype rocket outside the US and China to pull off a flight like this. The company said the launch and landing test demonstrated "key technologies essential for rocket reusability, such as flight stability during ascent and descent, as well as landing capability". The Japanese car manufacturer first revealed in 2021 that it had been working on a rocket engine for at least two years. After six years of development, this successful test marked a major step in Honda's push into space innovation. But Honda is not alone in the race beyond Earth. Other car makers like Geely, GM, Hyundai-Kia, Toyota and Venturi are partnering with space tech companies. Unlike Honda and Venturi that have developed rockets or space vehicles, Toyota has been involved more in robotics and space exploration tech. Vid shows supersonic test launch in bid for 1hr cross-Atlantic flights in 5yrs Geely, GM and Hyundai-Kia are partnering with aerospace firms or investing in space tech startups - rather than independently developing rockets yet. It comes after talk of a merger between car rivals Nissan and Honda collapsed in February. But the door to collaboration remains wide open. Nissan's CEO Ivan Espinosa said in March that the company is "very open" to partnerships. The company's chief performance officer, Guillaume Cartier, said Nissan had "never stopped" talking with its Japanese rival, confirming that the two continue working towards a potential partnership. Espinosa, who officially took over on April 1, said his company faces up to five simultaneous crises - including a damaged brand, low morale and the execution of a sweeping turnaround. Speaking at a company event, he said: "The way we are seeing partners is broadly, not only thinking about cars but how to push Nissan into the next era of technology." Toshihiro Mibe has been the CEO of Honda Motor Co. since 2021.
Reuters
7 hours ago
- Reuters
Magnitude 6 earthquake strikes off coast of Hokkaido, Japan, GFZ says
June 21 (Reuters) - A Magnitude 6 earthquake struck off coast of Hokkaido, Japan on Sunday, the German Research Centre for Geosciences (GFZ) said. The quake was at a depth of 10 km (6.21 miles), GFZ said.
Reuters
9 hours ago
- Reuters
China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds
June 21 (Reuters) - Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a similar drug sold by Novo Nordisk ( opens new tab, according to a late-stage study published on Saturday. The drug, called ecnoglutide, belongs to a class of drugs that include Novo's Wegovy called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. "It's going to be competitive," said Dr. Tricia Tan of Imperial College London, who wrote a piece accompanying the data which appeared in medical journal The Lancet. Tan said additional GLP-1s on the market could potentially drive prices down and improve access globally. "It's great to have competition in the market. It's been extremely frustrating - I work in the National Health Service and patients are not getting access to these drugs." Patients have seen even better results with Eli Lilly's (LLY.N), opens new tab Zepbound, which stimulates GLP-1 as well as a second gut hormone called GIP. More than 20% weight loss was reported in clinical trials. According to the Sciwind Phase 3 study, 499 patients were given 1.2 mg, 1.8 mg or 2.4 mg of ecnoglutide as a subcutaneous injection once weekly for 48 weeks, with 165 patients assigned to receive a placebo. The study was conducted at 36 medical centers across China. The patients who received the 1.2 mg dose lost an average of 9.9% of their body weight after 48 weeks, and those who received the 1.8 mg dose lost an average of 13.3% of their body weight. Patients on the 2.4 mg dose lost an average of 15.4% of their body weight. The patients on placebo lost an average of 0.3% of their body weight over the period. The side-effect profile is not significantly different from the other weight loss drugs. Many of the patients given ecnoglutide experienced decreased appetite and gastrointestinal problems, including diarrhea, nausea and vomiting, the study authors wrote.
